LAG-3, the next outlet?

On March 18, 2022, the FDA officially approved the "first-in-class" product Opdualag of lymphocyte-activation gene-3 (LAG-3) for the treatment of patients with unresectable or metastatic melano.

LAG-3 structure (source: Immunological Reviews)

Professor Frédéric Triebel discovered LAG-3 in the late 198

Some listed and under-development LAG-3 projects (Source: Nature Reviews Drug Discovery)

*Relatlimab was approved for marketing on March 18, 202

"This is a transformative data," said Jason Luke, an oncologist at the University of Pittsburgh Medical Center who has advised BMS after the Phase II/III data for relatlimab and nivolum.

From being snubbed to counterattack

BMS began focusing on the immune checkpoint field as early as 2010 and attempted to initiate a clinical trial of Relatlimab in 201 Previously, preclinical data from BMS and other companies had shown little activity by blocking LAG-3 alo.

greater potential

Another therapeutic potential of LAG-3 is whether other tumors will respond positively to combined LAG-3 and PD-1 thera.

Tumors were classified based on immune scor.

However, pharmacologist Adam Palmer from the University of North Carolina School of Medicine is skeptic.

Competition is fierce

According to the NextPharma database, there are currently more than 20 LAG-3 products in clinical trials worldwi.

future breakthrough

Up to now, more than 10 PD-1/PD-L1 monoclonal antibodies have been approved for marketing in the world, providing new treatment options for dozens of tumo.

MHC II proteins, Galectin-3, LSECtin and FGL1 can all bind to LAG-3 (source: Seminars in Immunology)

These findings have brought new opportunities and challenges for drug development around LAG- Whether the LAG-3 pathway can produce more anti-cancer breakthroughs in the next 5-10 years deserves further expectati.

References:

[1] Asher Mulla.

[9] Jedd.

Wolchok et .

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melano.

The New England Journal of Medici.

201

[10] Jérôme Galon et .

Approaches to treat immune hot, altered and cold tumors with combination immunotherapi.

Nature Reviews Drug Discove.

201

[11] http:// [11] http:// [12] https://zhuanl.

zhi.

com/p/450850700

[13] Elisa Ruffo et .

Lymphocyte-activationgene 3 (LAG3): The next immune check point recept.

Seminars in Immunolo.

201